scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1012905709 |
P356 | DOI | 10.1186/S13045-015-0229-Y |
P932 | PMC publication ID | 4702409 |
P698 | PubMed publication ID | 26733151 |
P5875 | ResearchGate publication ID | 289502069 |
P50 | author | Hui-Chuan Sun | Q90958061 |
P2093 | author name string | Ning Zhang | |
Zhao-You Tang | |||
Yi-Ming Zhao | |||
Dong-Mei Gao | |||
Xiao-Dong Zhu | |||
Zong-Tao Chai | |||
Bo-Gen Ye | |||
Cheng-Hao Wang | |||
Man-Qing Cao | |||
Wei-Ping Zhu | |||
De-Ning Ma | |||
Cheng-Dong Qin | |||
Di-Hua Zhan | |||
P2860 | cites work | Widespread microRNA repression by Myc contributes to tumorigenesis | Q24647067 |
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. | Q37721840 | ||
Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer | Q38021354 | ||
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. | Q38040369 | ||
Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma | Q38883619 | ||
Effects of EZH2 gene on the growth and migration of hepatocellular carcinoma HepG2 cells | Q41955698 | ||
MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway | Q46255425 | ||
MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway | Q47616223 | ||
The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma. | Q51515581 | ||
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. | Q53376881 | ||
Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues | Q71007109 | ||
Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma | Q73746406 | ||
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker | Q84025680 | ||
MicroRNAs in cancer | Q86065522 | ||
MicroRNA expression, survival, and response to interferon in liver cancer | Q24647241 | ||
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 | ||
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
Molecular mechanisms of epithelial-mesenchymal transition | Q27013743 | ||
Incomplete radiofrequency ablation enhances invasiveness and metastasis of residual cancer of hepatocellular carcinoma cell HCCLM3 via activating β-catenin signaling | Q27318569 | ||
Global cancer statistics, 2012 | Q27860501 | ||
MicroRNA signatures in human cancers | Q27860962 | ||
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 | Q27861068 | ||
MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin | Q28263940 | ||
Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer | Q28295895 | ||
MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2 | Q28302211 | ||
Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma | Q28304953 | ||
Complex networks orchestrate epithelial-mesenchymal transitions | Q29547478 | ||
The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 | ||
A causal role for E-cadherin in the transition from adenoma to carcinoma | Q29616122 | ||
Hepatocellular carcinoma | Q29616359 | ||
Tumor metastasis: mechanistic insights and clinical challenges | Q29617676 | ||
Mechanisms of fibrogenesis in liver cirrhosis: The molecular aspects of epithelial-mesenchymal transition | Q33563882 | ||
Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancer | Q33875021 | ||
Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma | Q33947429 | ||
E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. | Q34088774 | ||
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. | Q34561758 | ||
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis | Q34933986 | ||
MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma | Q35032496 | ||
miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation | Q35176071 | ||
microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. | Q35684366 | ||
Hepatocellular carcinoma: focus on different aspects of management | Q35986436 | ||
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer | Q36070061 | ||
Polycomb group protein EZH2-mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma | Q36105152 | ||
Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? | Q36197875 | ||
Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. | Q36415612 | ||
miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2 | Q36774599 | ||
Epithelial-mesenchymal transition in hepatocellular carcinoma. | Q37620382 | ||
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. | Q37625446 | ||
P921 | main subject | microRNA | Q310899 |
hepatocellular carcinoma | Q1148337 | ||
P304 | page(s) | 1 | |
P577 | publication date | 2016-01-06 | |
P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
P1476 | title | MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. | |
P478 | volume | 9 |
Q37741143 | Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy |
Q52726443 | Cell Cycle Regulation of Stem Cells by MicroRNAs. |
Q42316356 | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China |
Q44646012 | Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets. |
Q41552639 | Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer |
Q50485266 | Dynamic microRNAome profiles in the developing porcine liver. |
Q55241876 | Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma. |
Q56889801 | Epigenetic mechanisms of tumor resistance to immunotherapy |
Q38993869 | Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. |
Q52349529 | Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. |
Q33732998 | Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma |
Q91706089 | Genetic And Epigenetic Regulation Of E-Cadherin Signaling In Human Hepatocellular Carcinoma |
Q33865244 | Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo |
Q37099828 | Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I. |
Q37728657 | Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer |
Q39376074 | Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes |
Q60044741 | LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway |
Q38736898 | Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. |
Q38750019 | MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells. |
Q38714879 | MiR-26a enhances invasive capacity by suppressing GSK3β in human lung cancer cells |
Q49790324 | MicroRNA-26a and Tumor |
Q49887992 | Molecular subtyping of nasopharyngeal carcinoma (NPC) and a microRNA-based prognostic model for distant metastasis. |
Q38746336 | Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients |
Q37440060 | Monoacylglycerol lipase promotes progression of hepatocellular carcinoma via NF-κB-mediated epithelial-mesenchymal transition |
Q92854613 | Roles of E-cadherin and Noncoding RNAs in the Epithelial-mesenchymal Transition and Progression in Gastric Cancer |
Q57470962 | Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors |
Q33794860 | The Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression. |
Q55024083 | The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. |
Q49545290 | The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies |
Q38796729 | The role of microRNA-26a in human cancer progression and clinical application |
Q38730915 | Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study |
Q92761624 | miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2 |
Q55315505 | miR-26a suppresses osteosarcoma migration and invasion by directly targeting HMGA1. |
Search more.